TCM
DNA icon

Traynor Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Traynor Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-250
Closed -$18.1K – 252
2023
Q3 		$18.1K Hold
250
– – ﹤0.01% 216
2023
Q2 		$18.6K Buy
+250
New +$14.8K ﹤0.01% 210

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Traynor Capital Management's DNA Position: Q4 2023 in Review

Traynor Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 197 shares — an estimated $14.3K sold.

Traynor Capital Management first reported a position in DNA in Q2 2023 and held it in 2 quarters. The position peaked at $14.3K in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

  • Traynor Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
  • Traynor Capital Management sold 197 Ginkgo Bioworks shares in Q4 2023, an estimated $14.3K.
  • Traynor Capital Management first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 2 quarters.
  • Traynor Capital Management's Ginkgo Bioworks position peaked at $14.3K in Q3 2023.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on Traynor Capital Management's 13F filing for Q4 2023, filed 18 Jan 2024.